We analyzed the transforming potential and TKIs responsiveness of three atypical BCR-ABL1 fusions identified in CML patients, and of two additional BCR-ABL1 constructs with lab-engineered breakpoints. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.